zota
healthcare ltd.

July 17, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Intimation of Acquisition of 2,35,512 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, on a preferential basis for consideration other than cash

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject; we, M/s Zota Health Care Limited (the “Company”), would like to inform you that the Company has acquired 2,35,512 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company (“WOS”), on a preferential basis for consideration other than cash, towards adjustment and discharge of the outstanding Unsecured loan together with outstanding accumulated interest thereto, granted by the Company to the WOS.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 are annexed herewith as ***(Annexure-1)***.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**
Ashvin Bhagavanbhai Variya

Ashvin Variya
(Group Company Secretary & Compliance Officer)

Place: Surat
Encl.: a/a

Registered Office:
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com
CIN: L24231GJ2000PLC038352

Annexure-1

Particulars	Details
Name of the target entity, details in brief such as size, turnover etc.	i. **Name of the Target Entity:** Davaindia Health Mart Limited ii. **Business of the Target Entity**: To operate retail Generic Pharmacy chain under Company Owned Company Operated (COCO) model of Davaindia Generic Pharmacy. iii. **Financial details:** As per the audited financial statements for FY 2025-26, the turnover of WOS was Rs. 267.71 crores and the total paid-up share capital was Rs. 2.71 crores.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The acquisition does not fall within related party transactions. The promoter/ promoter group/ group companies do not have any interest in WOS and the said transaction is done at arm's length basis.
Industry to which the entity being acquired belongs	Pharmaceutical
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company has acquired 2,35,512 equity shares of WOS on a preferential basis amounting to Rs. 1,19,52,23,400/- for consideration other than cash, through conversion of outstanding Unsecured loan together with outstanding accumulated interest thereto, granted by the Company to the WOS. The said investment would result into reduction in Group's total outstanding debt on a consolidated basis and improves overall net worth of the Group.
Brief details of any governmental or regulatory approvals required for the acquisition	N.A.
Indicative time period for completion of the acquisition	On July 17, 2026, the Company has acquired the 2,35,512 equity shares of WOS on a preferential basis for consideration other than cash.
Nature of consideration - whether cash consideration or share swap and details of the same;	Conversion of outstanding Unsecured loan granted by the Company to the WOS together with outstanding accumulated interest thereto, into equity shares of WOS on a preferential basis for consideration other than cash.
Cost of acquisition or the price at which the shares are acquired	Cost of acquisition for 2,35,512 equity shares is Rs. 5,075/ per equity share (including premium of Rs. 5,065/-) aggregating to Rs. 1,19,52,23,400/- through conversion of outstanding Unsecured loan together with outstanding accumulated interest thereto, in the books of accounts as stood at June 15, 2026.
Percentage of shareholding / control acquired and / or number of shares acquired	The Company has acquired 2,35,512 equity shares of WOS. Post to this acquisition, M/s Davaindia Health Mart Limited continues to remain as the Wholly Owned Subsidiary of the Company.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	M/s Davaindia Health Mart Limited was incorporated on January 01, 2020, domiciled in India; operating COCO stores of Davaindia Generic Pharmacy with 1,855 stores as at June 30, 2026 and offering 2000+ SKUs inclusive of Medicines, Ayurvedic, Cosmetics, Nutraceutical and OTC products. During last three financial years, the details of turnover of WOS were as follows: FY 2025-26 Rs. 267.71 crores FY 2024-25 Rs. 109.93 crores FY 2023-24 Rs. 44.77 crores